CDMO Catalent, which offers services for a full range of OINDPs, has announced the completion of the first phase of “a significant expansion” of its development and manufacturing capabilities for unit dose and bi-dose nasal sprays at its facility in Morrisville, NC, USA. The new additions include a high speed micro vial filling line and a high speed assembly line, the company said.
According to the announcement, the goal of the project is “to expand and modernize its nasal drug delivery capabilities, substantially increasing technology and capacity to support projected growth for existing and future customers” in response to growing demand. The Morrisville facility is home to Catalent’s center of excellence for nasal drug development.
Catalent President of Oral and Specialty Delivery Jonathan Arnold commented, “Our team in Morrisville has a long history of success in developing and commercializing nasal drug products, and we are witnessing a growth in this field from innovators looking to exploit its advantage, such as its fast onset of action and being non-invasive. This initial investment at the site has allowed us to integrate expertise across a range of disciplines, including analytical sciences, formulation development and manufacturing, with the latest in product filling technology, enabling researchers to accelerate nasal drug product programs, and commercialize new medicines as fast as possible.”
Read the Catalent press release.
